title: [Low-fluence photodynamic therapy in chronic central serous chorioretinopathy].
abstract: OBJECTIVE
  To evaluate safety and efficacy of low-fluence photodynamic therapy (LFPDT) with verteporfin in patients affected with chronic central serous chorioretinopathy (CCSC), in terms of visual acuity (VA) and macular morphology measured with optical coherence tomography (OCT).
  
  
  METHODS
  A retrospective, non-randomized and interventionist analysis was performed on 16 eyes in 15 patients with CCSC treated with LFPDT. Best corrected visual acuity (BCVA) with ETDRS optotypes and central foveal thickness (CFT) in OCT were evaluated as outcome measures.
  
  
  RESULTS
  The mean follow-up was 10.8 months. The mean BCVA improved from 58.12 to 68.68 ETDRS letters, and CFT decreased from 280.5 to 172.18 microns, with subretinal fluid resolution in 14 eyes (87.5%), two of them after a second LFTPD. No complications related to treatment were recorded.
  
  
  CONCLUSIONS
  LFPDT with verteporfin can be useful in CCSC to stabilise or improve BCVA, reabsorb subretinal fluid and reduce CFT. Randomised studies with a longer follow-up are required to assure the role of this treatment and to optimise parameters for higher efficacy and safety in CCSC patients.
authors.affiliation: Sección de Retina, Departamento de Oftalmología, Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, España. alcubierre82@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Alcubierre
authors.forename: L
authors.initials: L
authors.lastname: Arias
authors.forename: D
authors.initials: D
authors.lastname: Lorenzo
authors.forename: O
authors.initials: O
authors.lastname: Pujol
authors.forename: M
authors.initials: M
authors.lastname: Rubio
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005584:Fovea Centralis / Q000648:ultrastructure; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin